These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30119908)

  • 41. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
    Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
    Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E; Plunkett W; Gandhi V; Rios MB; Kantarjian H; Keating MJ
    Leuk Lymphoma; 1993 Mar; 9(4-5):343-50. PubMed ID: 8394169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.
    Tosi P; Visani G; Ottaviani E; Manfori S; Zinzani PL; Tura S
    Leukemia; 1994 Dec; 8(12):2076-82. PubMed ID: 7528855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W
    Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
    Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
    J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L; Plunkett W; Liliemark J; Gandhi V; Iacoboni S; Keating M
    Leukemia; 1987 Sep; 1(9):638-43. PubMed ID: 3478543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
    Hubeek I; Litvinova E; Peters GJ; Broekhuizen R; Haarman EG; Huismans DR; Cloos J; Zwaan CM; Fleischhack G; Creutzig U; Kaspers GJ
    Int J Oncol; 2004 Dec; 25(6):1823-9. PubMed ID: 15547723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
    Ahlmann M; Lanvers C; Lümkemann K; Rössig C; Freund A; Baumann M; Boos J
    Leukemia; 2001 Jan; 15(1):69-73. PubMed ID: 11243402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V; Plunkett W
    Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
    Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
    Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
    Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
    Estey EH; Thall PF; Cortes JE; Giles FJ; O'Brien S; Pierce SA; Wang X; Kantarjian HM; Beran M
    Blood; 2001 Dec; 98(13):3575-83. PubMed ID: 11739159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
    Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
    Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
    Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
    Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical pharmacology of nucleoside analogues].
    Milano G; Chamorey AL; Thyss A
    Bull Cancer; 2002 Aug; 89 Spec No():S71-5. PubMed ID: 12449033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.